Category
162 articles — page 8 of 14
Ruxolitinib cream (Opzelura) and tacrolimus are the two most-discussed topical treatments for vitiligo. They work by different mechanisms, have different evidence bases, and suit different patients. Here is the direct head-to-head comparison.
Tofacitinib is an oral JAK inhibitor used off-label for vitiligo, with a growing body of case series and small trial evidence. It predates ruxolitinib and baricitinib as a JAK inhibitor in clinical use, but carries a more complex safety profile.
Vitiligo and alopecia areata co-occur more frequently than chance would predict, share autoimmune mechanisms, and — critically — both respond to JAK inhibitors. Understanding the overlap has real treatment implications.
Atopic dermatitis (eczema) co-occurs with vitiligo at elevated rates, and both conditions respond to topical calcineurin inhibitors. Here is how to manage the two together without treatments conflicting.
Vitiligo and lupus co-occur more frequently than chance predicts and share immune mechanisms. For patients with both conditions, treatment choices interact in important ways that require coordinated specialist care.
Vitiligo on visible areas adds an extra layer to the already complicated experience of dating. When to disclose, how to handle early conversations, and how to build the confidence that makes dating with vitiligo work.
Co-occurrence of vitiligo and psoriasis is documented and more common than chance predicts. JAK inhibitors have evidence for both conditions, creating a treatment opportunity for patients with the overlap.
Perioral vitiligo — patches around the mouth — is highly visible, emotionally difficult, and presents specific treatment challenges distinct from lip vitiligo or general facial vitiligo. Here is what works and what to expect.
Clinical trials offer access to cutting-edge vitiligo treatments before they are widely approved, at no drug cost. Here is how to find active trials, assess eligibility, and understand what participation actually involves.
Tattooing over or around vitiligo patches is possible, but Koebner risk is real and the cosmetic outcomes are unpredictable on depigmented skin. Here is what dermatologists say and what to consider before proceeding.
Vitiligo affects people of all skin tones, but the experience on darker skin is meaningfully different — higher contrast, greater stigma, and specific treatment considerations. Here is what the research and patient experience actually show.
Vitiligo developing or worsening during adolescence intersects with identity formation, peer perception, and school life in ways specific to this age group. Here is the treatment picture for teenagers and the broader context that matters.
